GlassScriptPhysician profile
Latha T Nair
NPI 1164527560
$451,167.33
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101K · 2020: $23K · 2021: $69K · 2022: $151K · 2023: $106K · 2024: $2,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Travel and Lodging: $24K · Consulting Fee: $5,738 · Food and Beverage: $3,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,346.50 |
| Travel and Lodging | $23,818.08 |
| Consulting Fee | $5,738.00 |
| Food and Beverage | $3,789.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $260,847.13 | 2019-2024 | Invega Sustenna, Invega Trinza, Invega |
| Alkermes, INC. | $87,690.00 | 2019-2023 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $49,420.17 | 2019-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $25,038.67 | 2019-2023 | Rexulti |
| Indivior INC. | $17,873.69 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $9,145.60 | 2019-2020 | |
| Allergan, INC. | $552.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $231.11 | 2021-2023 | Uzedy |
| Abbvie INC. | $211.50 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $157.11 | 2022-2023 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latha Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.